反応式
Cl[CH2:2][C:3]([N:5]([CH2:23][CH:24]1[CH2:26][CH2:25]1)[CH2:6][CH2:7][C:8]1[NH:9][C:10]2[C:15]([C:16]=1[C:17]1[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=1)=[CH:14][CH:13]=[CH:12][CH:11]=2)=[O:4]>C(Cl)Cl.[Br-].C([N+](CCCC)(CCCC)CCCC)C1C=CC=CC=1.[OH-].[Na+].O>[CH:24]1([CH2:23][N:5]2[CH2:6][CH2:7][C:8]3=[C:16]([C:17]4[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=4)[C:15]4[CH:14]=[CH:13][CH:12]=[CH:11][C:10]=4[N:9]3[CH2:2][C:3]2=[O:4])[CH2:26][CH2:25]1参加物
反応物 1
生成物 1
試薬・触媒・溶媒 4
実験手順
A solution of 184.3 g 2-chloro-N-cyclopropylmethyl-N-[2-(3-phenyl-1H-indol-2-yl)ethyl]acetamide in 1843 ml methylene chloride is added dropwise under vigorous stirring to a suspension of 17.9 g N-benzyltributyl-ammoniumbromide in 1843 ml methylene chloride and 921 ml 30% sodium hydroxide. The mixture is stirred for further 10 minutes and diluted with 1 l water. The organic phase is separated, washed with water, dried and evaporated to dryness. The residue is dissolved in 500 ml boiling ethanol, cooled and treated with 500 ml ether. The resulting cristalline precipitate is filtered off, washed with ethanol/ather (1:1) and then ether to give 2,3-dihydro-3-cyclopropylmethyl-11-phenyl-1H-[1,4]diazepino[1,7-a]indol-4(5H)-one, m.p. 149°-150°.
後処理
- customThe organic phase is separated
- washwashed with water
- customdried
- customevaporated to dryness
- dissolutionThe residue is dissolved in 500 ml
- temperaturecooled
- additiontreated with 500 ml ether
- filtrationThe resulting cristalline precipitate is filtered off
- washwashed with ethanol/ather (1:1)
出典と根拠
- ORDレコード
- ord-269af1cc43ba49e99273bb649c792914
- 出典データセット
- uspto-grants-1987_06
- 特許番号
- US04673674
関連ノート
読み込み中…